Pharma-Bio Serv, Inc.
No SEC Form 4 filings for $PBSV in the last 30 days.
See all $PBSV insider activity →Pharma-Bio Serv, Inc. (PBSV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 September 14, 2026 Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026 DORADO, PR / ACCESS Newswire / September 14, 2026 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology trans
Pharma-Bio Serv, Inc. (PBSV) filed an SEC Form 8-K — Results of Operations and Financial Condition. pbsv_8k.htm 0001304161 false 0001304161 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 D
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PBSV (Pharma-Bio Serv, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Small revenue increase and narrowed loss suggest modest operational improvement.
This is a routine earnings/operations disclosure via 8-K; the filing itself doesn’t include the numeric results in the provided text.
AlphAI scores every news story that mentions PBSV with an AI model for sentiment and relevance, and aggregates insider trades from Pharma-Bio Serv, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pharma-Bio Serv, Inc. (PBSV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 September 14, 2026 Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026 DORADO, PR / ACCESS Newswire / September 14, 2026 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology trans
1 min readPharma-Bio Serv, Inc. (PBSV) filed an SEC Form 8-K — Results of Operations and Financial Condition. pbsv_8k.htm 0001304161 false 0001304161 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 D
2 min read